Year |
Citation |
Score |
2022 |
Dambra R, Matter A, Graca K, Akhand SS, Mehta S, Bell-Cohn A, Swenson JM, Abid S, Xin D, Lewis C, Coyle L, Wang M, Bunosso K, Maugiri M, Ruiz R, ... ... Vigil A, et al. Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication. Molecular Therapy. Methods & Clinical Development. 28: 190-207. PMID 36700123 DOI: 10.1016/j.omtm.2022.12.013 |
0.515 |
|
2020 |
Vigil A, Frias-Staheli N, Carabeo T, Wittekind M. Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies. Journal of Virology. 94. PMID 32847855 DOI: 10.1128/JVI.00052-20 |
0.462 |
|
2018 |
Vigil A, Estélles A, Kauvar LM, Johnson SK, Tripp RA, Wittekind M. Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses. Antimicrobial Agents and Chemotherapy. PMID 29507069 DOI: 10.1128/AAC.02269-17 |
0.452 |
|
2009 |
Zamarin D, Martínez-Sobrido L, Kelly K, Mansour M, Sheng G, Vigil A, García-Sastre A, Palese P, Fong Y. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 697-706. PMID 19209145 DOI: 10.1038/Mt.2008.286 |
0.548 |
|
2008 |
Vigil A, Martinez O, Chua MA, García-Sastre A. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1883-90. PMID 18714310 DOI: 10.1038/mt.2008.181 |
0.463 |
|
2007 |
Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, Martínez-Sobrido L, Woo SL, García-Sastre A. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Research. 67: 8285-92. PMID 17804743 DOI: 10.1158/0008-5472.Can-07-1025 |
0.46 |
|
Show low-probability matches. |